UCB SA (UNC.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:UNC - BE0003739530 - Common Stock
UNC.DE Key Statistics, Chart & Performance
The current stock price of UNC.DE is 223.6 EUR.
UNC.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.36 | 210.22B | ||
| SNW.DE | SANOFI | 11.34 | 209.38B | ||
| SAN.PA | SANOFI | 11.37 | 210.44B | ||
| MRK.DE | MERCK KGAA | 13.53 | 50.17B | ||
| UCB.BR | UCB SA | 36.78 | 45.92B | ||
| 1BAYN.MI | BAYER AG-REG | 5.75 | 30.18B | ||
| BAYN.DE | BAYER AG-REG | 5.77 | 30.29B | ||
| IPN.PA | IPSEN | 12.47 | 10.74B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.74 | 10.60B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.78 | 9.34B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.96 | 9.07B | ||
| VIRP.PA | VIRBAC SA | 20.85 | 3.03B |
Related stock screener links
About UNC.DE
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UNC.DE FAQ
Can you describe the business of UCB SA?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Can you provide the latest stock price for UCB SA?
The current stock price of UNC.DE is 223.6 EUR. The price decreased by -2.14% in the last trading session.
What is the dividend status of UCB SA?
UCB SA (UNC.DE) has a dividend yield of 0.42%. The yearly dividend amount is currently 1.36.
What is the ChartMill technical and fundamental rating of UNC stock?
UNC.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What sector and industry does UCB SA belong to?
UCB SA (UNC.DE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for UCB SA?
UCB SA (UNC.DE) will report earnings on 2026-02-26, after the market close.
UNC.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to UNC.DE.
UNC.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UNC.DE. UNC.DE has an average financial health and profitability rating.
UNC.DE Financial Highlights
Over the last trailing twelve months UNC.DE reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.45% | ||
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| Debt/Equity | 0.29 |
UNC.DE Forecast & Estimates
25 analysts have analysed UNC.DE and the average price target is 253.39 EUR. This implies a price increase of 13.32% is expected in the next year compared to the current price of 223.6.
For the next year, analysts expect an EPS growth of 54.7% and a revenue growth 23.1% for UNC.DE